Metsera, Inc.
MTSR
Rangering i aksjer
#2575
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Aksjekurs
$70.50
Sist synkronisert: 2025-11-14
Markedsverdi
$7.33B
Endring (1 dag)
0.00%
Endring (1 år)
33.60%
Land
US
Handel Metsera, Inc. (MTSR)
Kategori
Healthcare
Historikk for aksjesplitt for Metsera, Inc. (MTSR)
Aksjen Metsera, Inc. (symbol: MTSR) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Oct 22, 2026.
Én MTSR-aksje kjøpt før Oct 22, 2026 tilsvarer i dag 0 MTSR-aksjer.
Den nyeste splittelsen skjedde Oct 22, 2026.
Én MTSR-aksje kjøpt før Oct 22, 2026 tilsvarer i dag 0 MTSR-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| Ikke nok data for de angitte datoene. | |||
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|
